| |
| |
|
| Insider
Information: |
Liau Gene |
| Relationship: |
EVP Research & Preclin... |
| City: |
Bedford |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
21,351 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
21,351 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Stoke Therapeutics, Inc. |
STOK |
EVP Research & Preclin... |
2021-03-02 |
21,351 |
2019-12-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2021-03-02 |
4 |
AS |
$62.46 |
$327,546 |
D/D |
(5,195) |
21,351 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2021-03-02 |
4 |
OE |
$0.60 |
$3,117 |
D/D |
5,195 |
26,546 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-12-28 |
4 |
AS |
$58.73 |
$8,751 |
D/D |
(149) |
21,351 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-12-28 |
4 |
OE |
$0.60 |
$4,800 |
D/D |
8,000 |
21,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-19 |
4 |
AS |
$37.64 |
$1,210,164 |
D/D |
(32,000) |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-19 |
4 |
OE |
$0.60 |
$21,590 |
D/D |
32,000 |
45,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-16 |
4 |
AS |
$40.00 |
$234,042 |
D/D |
(5,851) |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-16 |
4 |
OE |
$0.60 |
$3,511 |
D/D |
5,851 |
19,351 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-13 |
4 |
AS |
$40.00 |
$65,960 |
D/D |
(1,649) |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-10-13 |
4 |
OE |
$0.60 |
$989 |
D/D |
1,649 |
15,149 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-06-01 |
4 |
AS |
$25.82 |
$527,037 |
D/D |
(20,000) |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-06-01 |
4 |
OE |
$2.19 |
$43,800 |
D/D |
20,000 |
33,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-05-22 |
4 |
AS |
$30.00 |
$225,000 |
D/D |
(7,500) |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-05-22 |
4 |
OE |
$0.60 |
$4,500 |
D/D |
7,500 |
21,000 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2020-03-31 |
4 |
OE |
$0.60 |
$4,500 |
D/D |
7,500 |
13,500 |
0 |
- |
|
| STOK |
Stoke Therapeutics, Inc. |
EVP Research & Preclinical Dev |
• – – |
2019-12-20 |
4 |
OE |
$0.60 |
$3,600 |
D/D |
6,000 |
6,000 |
0 |
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
